Core Insights - Elutia Inc. has announced that Dr. Michelle LeRoux Williams, the Chief Scientific Officer, received the Medical Device Innovator Award for her contributions to the medical device industry, particularly for the development of EluPro™ [1][2] - EluPro™ is recognized as the world's first FDA-cleared antibiotic-eluting bioenvelope for cardiac implantable electronic devices (CIEDs), addressing significant complications associated with these devices [1][2][3] Company Overview - Elutia specializes in developing and commercializing drug-eluting biomatrix products aimed at improving compatibility between medical devices and patients [4] - The company focuses on humanizing medicine to enhance patient outcomes, particularly for those requiring implantable technologies [4] Product Details - EluPro™ combines a soft, regenerative biomatrix with antibiotics rifampin and minocycline to mitigate complications such as infection, migration, and skin erosion, which occur in 5-7% of the over 600,000 CIEDs implanted annually in the U.S. [3] - The product has received FDA clearance for use across all major CIED products, including pacemakers and implantable defibrillators, as well as neurostimulation devices [2][3]
Dr. Michelle LeRoux Williams Earns Washington Business Journal’s Medical Device Innovator Award